Emily Chan

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

Juthamas Sukbuntherng, Robert A Blake, Guangmin Li, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Oncogenic ERBB3 mutations in human cancers.

Somasekar Seshagiri, Jeremy Stinson, Charles Eigenbrot, 2013, Cancer cell.

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

Jane Fridlyand, Antoni Ribas, Timothy R. Wilson, 2012, Nature.